This page contains regularly updated information on Realm Therapeutics AIM securities and the Company's most significant shareholders. Realm Therapeutics is traded on AIM and no other Exchanges. There are no restrictions on the trading of Realm Therapeutics' shares
As of 21 February 2019
Number of AIM securities in issue: 116,561,917 10p Ords
There are no shares held in treasury.
Percentage of AIM Securities not in public hands: 35.62%
As of 21 February 2019, the following shareholders held interests in excess of 3% of ordinary share capital.
|BVF Partners LP||15,322,266||13.15%|
|BAVARIA Industries Group AG||6,944,948||5.96%|
|Abingworth BioEquities Master Fund Ltd.||6,384,277||5.48%|
|Sussex Trading Company Limited||6,148,880||5.28%|
|Oracle Management Limited||5,410,196||4.64%|
|Kanton Services Limited||4,629,196||3.97%|
|Invesco Asset Management, as agent for and on behalf of its discretionary managed clients||3,865,867||3.32%|
|Polar Capital Funds Plc||3,500,000||3.00%|
* Executive Director